Trial Profile

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients with At Risk of Progression Alport Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vonafexor (Primary)
Indications Hereditary nephritis
Focus Adverse reactions; Proof of concept
Acronyms ALPESTRIA-1
Sponsors ENYO Pharma

Most Recent Events

12 Jun 2025 According to an ENYO Pharma media release, company announced the smooth continuation of its Phase 2 ALPESTRIA-1 trial in 26 Alport syndrome patients. The topline results from the trial are on track for the fourth quarter of 2025.
27 Jan 2025 Status changed from recruiting to active, no longer recruiting.
31 Jul 2024 Planned initiation date changed to 31 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com